Status:
COMPLETED
Improved Prostate Cancer Diagnosis - Combination of Magnetic Resonance Imaging and Biomarkers
Lead Sponsor:
Turku University Hospital
Collaborating Sponsors:
University of Turku
Conditions:
Prostate Cancer
Eligibility:
MALE
40-85 years
Phase:
NA
Brief Summary
Prostate cancer has been the most common cancer in men in Finland over the last ten years. Prostate-specific antigen (PSA) plays an important role in screening of prostate cancer. However, PSA has a l...
Eligibility Criteria
Inclusion
- Age: 40 to 85 years
- Clinical suspicion of prostate cancer based on: serum level of PSA from 2,5 ng/ml to 25 ng/ml in two following measurements and/or abnormal digital rectal examination
- Mental status: Patients must be able to understand the meaning of the study
- Informed consent: The patient must sign the appropriate Ethics Committee (EC) approved informed consent documents in the presence of the designated staff
Exclusion
- previous prostate biopsy in the last 6 months
- previous diagnosis of prostate carcinoma
- previous prostate surgeries, e.g. TURP (transurethral prostatic resection)
- symptomatic of acute prostatitis
- contraindications for MRI (cardiac pacemaker, intracranial clips etc)
- uncontrolled serious infection
- claustrophobia
- any other conditions that might compromise patients safety, based on the clinical judgment of the responsible urologist
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2015
Estimated Enrollment :
175 Patients enrolled
Trial Details
Trial ID
NCT01864135
Start Date
March 1 2013
End Date
November 1 2015
Last Update
January 21 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Turku University Hospital
Turku, Finland, 20521